It seems that
barely a month goes by without a headline touting a new way of detecting, understanding or treating cancer. Whether it is a newly identified gene or protein
in the blood, tracing biological fingerprints, known as biomarkers, can be a valuable and rapidly growing part of medical research.
Cancer treatment is one area where the era of personalized
medicine is arriving, according to market research publisher Kalorama Information. In its recent report, “The Worldwide Market for Cancer Diagnostics,”
Kalorama predicts a $90 million market for pharmacodiagnostics, tests that determine whether a treatment matches the individual patient, by 2014.
An international team led by scientists from the Scripps Research Institute, the Swiss Tropical
Institute, the Genomics Institute of the Novartis Research Foundation (GNF) and the Novartis Institute for Tropical Diseases has discovered a drug candidate
that represents a potentially new class of drugs to treat malaria.
Combining multispectral imaging with advanced image analysis tools to perform tissue cytometry rapidly and on
a large scale and using many markers at once has proven to enable a better understanding of the mechanism of disease and potentially better, more precise
avenues of treatment.